Cases & Deals

  • Home
  • Practices
  • CTI Life Sciences Fund, Panacea Venture, and 3B Future Health Fund co-lead $42 million Series A funding of Domain Therapeutics

Share

CTI Life Sciences Fund, Panacea Venture, and 3B Future Health Fund co-lead $42 million Series A funding of Domain Therapeutics

April 2022

Client(s) CTI Life Sciences Fund, Panacea Venture, and 3B Future Health Fund

Jones Day represented CTI Life Sciences Fund, Panacea Venture, and 3B Future Health Fund as co-leaders in the $42 million Series A financing round of Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, along with other investors.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.